Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
Weijian Guo, Xiaofeng Wang(Nanjing University of Chinese Medicine), Li‐Xin Qiu(Fudan University Shanghai Cancer Center), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Wenhua Li(University of Hong Kong), Xin Liu(Qingdao University), Xiaowei Zhang(Fudan University Shanghai Cancer Center), Chenchen Wang(Shanghai Medical College of Fudan University), Zhe Zhang(Peking University), Wen Zhang(Xidian University), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Yusheng Wang(Hunan Agricultural University), Yifu He, Wanjing Feng(Fudan University Shanghai Cancer Center), Jun Wu(Key Laboratory of Nuclear Radiation and Nuclear Energy Technology), Lei Yang(Nantong Tumor Hospital), Mingzhu Huang(Fudan University Shanghai Cancer Center), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhiyu Chen(Chongqing University), Xiaoying Zhao(Fudan University Shanghai Cancer Center)
Cited by 2
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412